Humanalbumin Kedrion

Humanalbumin Kedrion is a sterile solution for injection containing human albumin as the active ingredient. It is supplied in a standard concentration (typically 20% w/v) and is marketed in the European Union as a prescription‑only plasma volume expander. The product is manufactured under GMP conditions, stored refrigerated, and intended for intravenous administration by healthcare professionals. It provides exogenous albumin to support oncotic pressure in patients with hypovolemia or hypoalbuminemia.

Humanalbumin Kedrion is used in clinical settings where rapid plasma volume expansion is required. It may be administered to support circulatory function in several medical situations.

- Management of hypovolemic shock due to trauma, surgery, or severe dehydration. - Treatment of burns patients with significant fluid loss and plasma protein depletion. - Support for patients with liver disease or nephrotic syndrome experiencing hypoalbuminemia. - Volume replacement during cardiac surgery or extracorporeal circulation procedures. - Adjunct therapy in therapeutic plasma exchange to maintain oncotic balance. - Resuscitation of patients with severe sepsis or septic shock when albumin levels are critically low.

Adverse reactions to Humanalbumin Kedrion are generally infrequent but can range from mild infusion‑related events to rare serious complications.

Common: - Mild fever, chills, or flushing during or shortly after infusion. - Transient hypotension or hypertension that resolves without intervention. - Nausea, vomiting, or mild abdominal discomfort. - Localized pain or erythema at the infusion site.

Serious: - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Acute hemolysis or renal impairment associated with volume overload. - Transmission of infectious agents, although risk is minimized by donor screening. - Thromboembolic events such as deep vein thrombosis or pulmonary embolism.

Humanalbumin Kedrion should be administered only by qualified healthcare professionals who assess patient history and monitor for potential risks.

- Verify the product’s expiration date and inspect for particulate matter before use. - Assess for known hypersensitivity to human albumin or any component of the solution. - Use caution in patients with congestive heart failure, pulmonary edema, or severe renal disease due to risk of fluid overload. - Adjust infusion rate in individuals with unstable hemodynamics or severe hypotension. - Avoid use in patients with active infection where increased oncotic pressure may exacerbate edema. - Monitor serum albumin levels and fluid balance during and after administration. - Document any adverse reactions and report them according to pharmacovigilance guidelines.

Humanalbumin Kedrion can affect the pharmacokinetics of concurrently administered drugs and may interact with certain medical conditions.

Avoid: - Concurrent use with high‑dose diuretics that may precipitate rapid intravascular volume shifts. - Administration alongside other colloid solutions (e.g., hydroxyethyl starch) without careful volume assessment.

Use with caution: - Vasopressor agents, as albumin infusion may potentiate blood pressure changes. - Anticoagulants, because altered plasma volume can influence coagulation parameters. - Nephrotoxic drugs, since volume expansion may affect renal clearance. - Immunosuppressive therapies, given potential changes in drug distribution.